Blocking Animal Biotech

By Miller, Henry I. | Regulation, Spring 2009 | Go to article overview

Blocking Animal Biotech


Miller, Henry I., Regulation


On January 15, the Food and Drug Administration announced "final guidance" on its regulatory policy toward "genetically engineered" animals. Typical of the agency's current mindset, the policy tortures the science and opts for the most stringent, stultifying regulatory approach among various possible choices. As a result, the new policy threatens the health of a promising new field: the production of animals with novel and valuable traits.

After more than 20 years of deliberation, the FDA's Center for Veterinary Medicine has stipulated that every genetically engineered animal will be subject to the procedures and regulations for drugs, such as pain relievers and anti-flea medicines, that are used to treat animal diseases. The rationale:

   The [Federal Food, Drug and
   Cosmetics Act] defines "articles
   (other than food) intended to
   affect the structure or any function
   of the body of man or other
   animals" as drugs. A [recombinant
   DNA] construct that is in a
   [genetically engineered] animal
   and is intended to affect the animal's
   structure or function meets
   the definition of an animal drug,
   whether the animal is intended
   for food, or used to produce
   another substance. Developers of
   these animals must demonstrate
   that the construct and any new
   products expressed from the
   inserted construct are safe for the
   health of the ... animal and, if
   they are food animals, for food
   consumption.

However, the introduction of a gene is not the same as the administration of a drug, which makes the FDA's rationale questionable. And it is noteworthy that the proposal represents a major shift in the regulation of biotechnology that will be hugely expensive to animal breeders and detrimental to consumers.

What kinds of animals are we talking about? One that has been awaiting an FDA policy for almost a decade is an Atlantic salmon that contains a Chinook salmon growth hormone gene that remains turned on all year (instead of during only the warmer months, as in nature). This cuts the salmon's time to reach a marketable adult weight from 30 months to 18. The extra gene confers no detectable differences in the salmon's appearance, taste, or nutritional value; it just grows faster--a tremendous economic advantage to those farming the fish. There are numerous other applications in various stages of research and development, including livestock with leaner muscle mass, enhanced resistance to disease, and improved use of dietary phosphorous to lessen the environmental effects of animal manure.

ANIMALS AND DRUGS Until now, the FDA has not regulated new lines of farm animals or, for that matter, animals used for what might be termed "medical purposes." For example, they do not regulate German shepherds or golden retrievers bred to enhance traits that make them better seeing-eye or companion dogs. The FDA has not even asserted its jurisdiction over genetically engineered animals crafted for research purposes, which include hundreds of lines of rodents.

The terminology in the FDA's policy announcement is itself interesting. The pre-marketing approval requirement only applies if the animal is crafted with recombinant DNA techniques. So, for example, if the salmon described above were to be the result of some sort of artificial insemination instead of recombinant DNA techniques, it would be exempt from pre-approval evaluation. In other words, the FDA's regulatory trigger is not the risk-related characteristics of an animal, but the use of a certain technology--and the most precise and predictable one, at that. That makes no sense.

[ILLUSTRATION OMITTED]

The "new drug" paradigm does not fit genetically engineered animals well. A far better model is the approach taken by another FDA unit, the Center for Food Safety and Nutrition, which places the burden of ensuring the safety of foods and food ingredients on those who produce them. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Blocking Animal Biotech
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.